Results 81 to 90 of about 556,392 (291)

Design and analysis strategies for robust microbiome ageing research

open access: yesFEBS Letters, EarlyView.
The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik   +5 more
wiley   +1 more source

Quantification of carbamylated LDL in human sera by a new sandwich ELISA

open access: yes, 2005
Background: We previously suggested that increased carbamylated LDL (cLDL), a product of nonenzymatic modification of LDL in human serum by urea-derived cyanate, may cause cardiovascular complications in patients with chronic renal insufficiency.
Alexei G Basnakian   +7 more
core   +1 more source

Reconstructing enzyme evolution by protein engineering

open access: yesFEBS Letters, EarlyView.
Natural enzyme evolution can be retraced by protein engineering methods such as directed evolution, rational design, and ancestral sequence reconstruction. These approaches reveal how enzymes emerged from ligand‐binding scaffolds, developed varying substrate preferences, formed oligomeric complexes, adapted to environmental changes, and evolved novel ...
Lukas Drexler   +2 more
wiley   +1 more source

Prevalence and pathogenic role of anti-EPO antibodies in patients treated with recombinant erythropoietin

open access: yes, 2004
56th Annual Meeting of the American-Association-for-Clinical-Chemistry -- JUL 25-29, 2004 -- Los Angeles, CA[Abstract Not Available]Amer Assoc Clin ...
Hoppensteadt, DA   +6 more
core  

Clinical chemistry education

open access: yes, 1976
This article is written to draw the attention of chemists and departments of chemistry to the discipline of clinical chemistry as deserving attention in undergraduate and postgraduate education and in its career possibilities for chemistry graduates. The
Curnow, D. H., Rao, C. N. R.
core   +1 more source

Population-based pediatric reference intervals in general clinical chemistry: A Swedish survey [PDF]

open access: yesJournal of Medical Biochemistry, 2015
Very few high quality studies on pediatric reference intervals for general clinical chemistry and hematology analytes have been performed. Three recent prospective community-based projects utilising blood samples from healthy children in Sweden, Denmark ...
Ridefelt Peter
doaj  

Health parameters in tail biters and bitten pigs in a case–control study

open access: yesAnimal, 2013
Health in relation to tail-biting behaviour was investigated on a problem farm. Quartets (n = 16) of age- and gender-matched fattening pigs including a tail biter (TB, n = 16), a victim (V, n = 16), a control in the same pen (Ctb, n = 10) and a control ...
C. Munsterhjelm   +4 more
doaj   +1 more source

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

open access: yesMolecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce   +11 more
wiley   +1 more source

Quality regulations and accreditation standards for clinical chemistry in Turkey

open access: yes, 2009
Objective: The purpose of this paper is to review the Current Status of laboratory quality regulations and accreditation standards in Turkey. Design and method: This paper is written based oil file Current regulations, information collected by available ...

core   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy